NCT01098526 - GSK1349572 Drug Interaction Study With Efavirenz | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2010

Primary Completion Date

May 26, 2010

Study Completion Date

May 26, 2010

Conditions

Infections, Human Immunodeficiency Virus and Herpesviridae

Interventions

DRUG

GSK1349572

GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.

DRUG

Efavirenz

Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.

Trial Locations (1)

GSK Investigational Site, Buffalo